Etoposide

目录号:S1225 别名: VP-16, VP-16213

Etoposide Chemical Structure

Molecular Weight(MW): 588.56

Etoposide是一种鬼臼毒素的半合成衍生物,通过抑制topoisomerase II 活性而抑制DNA合成。

规格 价格 库存 购买数量  
RMB 749.41 现货
RMB 575.72 现货
RMB 2290.17 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck该产品发表文献25篇:

产品安全说明书

Topoisomerase抑制剂选择性比较

生物活性

产品描述 Etoposide是一种鬼臼毒素的半合成衍生物,通过抑制topoisomerase II 活性而抑制DNA合成。
靶点
Topo II [2]
(Cell-free assay)
体外研究

Etoposide通过与Topoisomerase II 和 DNA形成复合物而抑制DNA合成,诱导双链DNA断裂,且阻碍通过 Topoisomerase II结合修复。DNA持续断裂阻碍进入细胞有丝分裂期,进而导致细胞死亡。Etoposide主要作用于细胞周期的G2期和S期。[1] Etoposide 抑制鼠类血管肉瘤细胞系 (ISOS-1) 生长,IC50 为0.25 μg/mL。Etoposide 抑制人类白血病成淋巴细胞系CCRF-CEM的四倍体克隆,IC50为0.6 μM。[3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Kelly MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX7JR|UxRTBwMUNihKnDueLCiUCuNFEh|ryP NVzBOZJDOjV7NkCyPFI>
KellyCis83 NXnqS3AyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkDZTWM2OD1yLkG25qCKyrIkgJmwMlAzKM7:TR?= MmrDNlU6PjB{OEK=
SK-N-AS MnXqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnGxTWM2OD1yLkK05qCKyrIkgJmwMlA{KM7:TR?= NITNSpkzPTl4MEK4Ni=>
SK-N-ASCis24 NXPHdmVXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWHJR|UxRTBwNUhihKnDueLCiUCuNVEh|ryP NHnXXYYzPTl4MEK4Ni=>
U87 MnHTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml3BNE02OCEQvF2= MoPtOFghcA>? NHyxWpBl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImge4hq[2hiY3HuJIJmKGWwaHHuZ4VlKGK7IIPpcIljcW6rbh?= NHTsSVczPTd3MEK3Ny=>
HCT116 M3TzTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXywMlUuOi53IN88US=> MVW0POKhcMLi NIXxWYFKSzVyPUGuO|PDqMLzwrCwMlIyyqEQvF2= NYf1[2ZNOjV5NE[3OlM>
HT-29 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEC0RYUxNjVvMj61JO69VQ>? NXHzeXp6PDkEoHlCpC=> NGn5OWVKSzVyPUeuNuKhyrIEoEGuNFTDqM7:TR?= M3XScVI2PzR4N{[z
Caco2 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1frOVAvPS1{LkWg{txO MkDUOFjDqGkEoB?= MVTJR|UxRTdwMkdCpOKyyqBzLk[4xsDPxE1? MmHmNlU4PDZ5NkO=
COLO 205 NF\0eHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlfPNE42NTJwNTFOwG0> MUW0POKhcMLi MnnlTWM2OD1zLk[xxsDDucLiMD6wNuKh|ryP MVOyOVc1Pjd4Mx?=
SW480 MnfxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGG4PYUxNjVvMj61JO69VQ>? MofqOFjDqGkEoB?= M2jjdWlEPTB;ND65NuKhyrIEoECuN|PDqM7:TR?= MX6yOVc1Pjd4Mx?=
HEK293T NF7Fc2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWSzWFV6OS13IN88US=> NXzFTJdlPDkEoHlCpC=> NFTRSFJKSzVyPUKuOFLDqMLzwrCwMlA2yqEQvF2= NWfHeZVqOjV5NE[3OlM>
Hep3B  NHfSbXJHfW6ldHnvckBCe3OjeR?= NH3QN|AyOCEQvF2= NXvEOlA3PDkEoHlCpC=> MXPy[YR2[2W|IITo[UBmdmijbnPpcoch\W[oZXP0JI9nKEKPUD22 MXmyOVY{OzV4NB?=
Hep3B  MoHXSpVv[3Srb36gRZN{[Xl? NIS3TGsxNjFvMUCg{txO M1HUOlI1KGh? MYnzeZBxemW|c3XzJJRp\SCneIDy[ZN{cW:wIH;mJIhmeGOrZHnuJI1TVkF? NIPQc48zPTZ|M{W2OC=>
HEK293 Mlr5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLpTWM2OD15LkG0xsDDucLiMD6zOuKh|ryP NH\KdXIzPTZyM{GyNi=>
DU145 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH7VNFJKSzVyPUKuNljDqMLzwrCwMlA1yqEQvF2= MoLENlU3ODNzMkK=
HCT15 Mo[2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlW5TWM2OD1yLkixxsDDucLiMD6wNeKh|ryP NX3NTnVxOjV4MEOxNlI>
T47D NWLXcVFUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTNwMUlCpOKyyqByLkGxxsDPxE1? NFfTfJkzPTZyM{GyNi=>
SMMC-7721 NGmyU5BHfW6ldHnvckBCe3OjeR?= MUe0NEDPxE1? M2DyXVQ5KGh? MXjEUXNQ NU\ye|R3cW6mdXPld{DPu0h{QWig[o9kcSCob4LtZZRqd25? NXfqfXhiOjV3NESzOlE>
MDA-MB-231 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUi2e4pMPzMEoHi= M1jwO2lEPTB;MkGuNuKhyrIEoESuNuKh|ryP MnPpNlU1QDZ{MUm=
MCF-7 M4nMZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTVPIFEPzMEoHi= NIC0RZNKSzVyPUGwMlnDqMLzwrCyMlHDqM7:TR?= MXyyOVQ5PjJzOR?=
Jurkat NIXuXIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlPPO|LDqGh? M3vVSmlEPTB;MT6yxsDDucLiMT61xsDPxE1? MkTONlU1QDZ{MUm=
HeLa MoS0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkfYO|LDqGh? MXvJR|UxRTNwOdMgxtHDqDJwM9Mg{txO NIO1[YUzPTR6NkKxPS=>
MCF7  MnvoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX3LRY5YPS1zMECg{txO NFzu[2w4KGR? MVzpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NF;rS2kzPTR5Mk[xPS=>
K562 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnTCO|LDqGh? M{ftb2lEPTB;MD6yPeKh|ryP MoTuNlUzQDJ4NUO=
K/VP.5 NW\zSolGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\1d5M4OsLiaB?= MWPJR|UxRTRwOdMg{txO MWmyOVI5OjZ3Mx?=
SH-EP  MUTGeY5kfGmxbjDBd5NigQ>? NXnmSHFnOjEEoN88[{9udA>? M2fsXFI1yqCq NIe3Z4pqdmO{ZXHz[ZMhfGinIHX4dJJme3Orb36gc4Yh\W6mb3flco92eyCGRWDQ NGWwPW0zPTJ4MUm4NS=>
SCC25 NXvGWYJvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkLsNlTDqGh? NXf1V4t5UUN3ME20N{4{yqEEsdMgNU4yOsLizszN NIHKS|IzPTJ{MEeyPS=>
CAL27 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlzUNlTDqGh? Mnj5TWM2OD13Mj6xxsDDucLiMT6wPeKh|ryP NGTVbGgzPTJ{MEeyPS=>
FaDu Ml\DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV\1[XRmOjUEoHi= NWDoXVhEUUN3ME2yOU45QcLiwsJCpFEvOTQEoN88US=> MUSyOVIzODd{OR?=
SCC25 NVrTNXRnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYnTO3c6PDkEoHi= M2i1UWlEPTB;MkCuPFbDqMLzwrCxMlA4yqEQvF2= NXTYbIhuOjV{MkC3Nlk>
CAL27 NHH2TGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYW0POKhcA>? Mn;ITWM2OD1zOD6yOOKhyrIEoEGuNVXDqM7:TR?= M1nsTlI2OjJyN{K5
FaDu MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{LJR|Q5yqCq NFXUUHVKSzVyPU[uOFPDqMLzwrCxMlE{yqEQvF2= MofWNlUzOjB5Mkm=
SCC25 M1XQTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVvyWWdzPzMEoHi= MlHCTWM2OD16LkSxxsDDucLiMT6xNeKh|ryP M2nocFI2OjJyN{K5
CAL27 NEnlPIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGTCU444OsLiaB?= M3myVmlEPTB;ND6yO:KhyrIEoEGuNVTDqM7:TR?= NULvTGt1OjV{MkC3Nlk>
FaDu MkjuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYXvbYc2PzMEoHi= NYL3cnk6UUN3ME21MlAzyqEEsdMgNU4yPcLizszN M{K2d|I2OjJyN{K5
MCF-7 Mn\qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn[xOFjDqGkEoB?= NILtT2lFVVOR NX;IZmxxUUN3ME23MlLDqMLzwrCwMljDqM7:TR?= MWGyOVIyPjN5OB?=
T-47D MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYD6NYVPPDkEoHlCpC=> Ml\uSG1UVw>? NXXZNGdnUUN3ME23MlfDqMLzwrCwMlfDqM7:TR?= NWjOZYtTOjV{MU[zO|g>
MDA-MB-231 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVr4fGFqPDkEoHlCpC=> NFn4NW9FVVOR NG[0XWpKSzVyPUGyMljDqMLzwrCxMlDDqM7:TR?= MWCyOVIyPjN5OB?=
DU145 M{jtPWFxd3C2b4Ppd{BCe3OjeR?= MmHvNVAuOTByIN88US=> NU\n[Zg5QCCq NFi5RoVFVVOR MmrDbY5lfWOnczDj[YxtKGSnYYToJJNq\26rZnnjZY51dHliaX6gZUB3\XK7IHzve{Bkd26lZX70doF1cW:w MVWyOVE1QTZ6MR?=
DU145 stem-like MknzRZBweHSxc3nzJGF{e2G7 Mm[wNVAuOTByIN88US=> M4Hv[VghcA>? MXPEUXNQ NHfzRo9qdmS3Y3XzJINmdGxiZHXheIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> Mo\JNlUyPDl4OEG=
DU145 NITXU5FHfW6ldHnvckBCe3OjeR?= NXPjXZlbOTBvMUCwJO69VQ>? NX3oSlE3OiCq NHLqVGNFVVOR M1PvdYlv[3KnYYPld{B1cGVicFPIT|Eh\XiycnXzd4lwdiCjbnSg[IVkemWjc3XzJJRp\SCyQ1jLNUBmgHC{ZYPzbY9vKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz M4nW[VI2OTR7Nkix
DU145 stem-like NH;PfopHfW6ldHnvckBCe3OjeR?= M1vHOVExNTFyMDFOwG0> NESwUnIzKGh? NF;EOnZFVVOR M3;pTYlv[3KnYYPld{B1cGVicFPIT|Eh\XiycnXzd4lwdiCjbnSg[IVkemWjc3XzJJRp\SCyQ1jLNUBmgHC{ZYPzbY9vKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MmrRNlUyPDl4OEG=
UW228-3 NETNbJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXGwMlAyNTNyMDFOwG0> MVK0PEBp MUnEUXNQ NESy[5FKSzVyPUCuPVnDqM7:TR?= MWeyOVEyQTF6NR?=
NSCs NGPSPFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXmwMlAyNTNyMDFOwG0> NEnQTVU1QCCq MXfEUXNQ NFTDSXpKSzVyPUCuN{0{yqEQvF2= NG\KPG8zPTFzOUG4OS=>
MKL-1  Mn;NSpVv[3Srb36gRZN{[Xl? NFX3WGkyOC1zMECwJI5O MnnIOEBl NFPON3dqdmS3Y3XzJJRp\SCrbnT1Z5Rqd25ib3[gUWhENUliZYjwdoV{e2mxbh?= MVyyOVEyPjd3NB?=
MCF7 EV NY\HVlYyTnWwY4Tpc44hSXO|YYm= M3jsTVExNTFyMDFOwG0> M2DYNlLjiImq MXPpcoR2[2W|IIDyc4R2[3Srb36gc4bDqM7|SELBXC=> MWCyOVA5QDJyMx?=
MCF 7BMI1 M3GzcmZ2dmO2aX;uJGF{e2G7 M1q3SVExNTFyMDFOwG0> NU\GNZA{OuLCiXi= NXLmWI1xcW6mdXPld{Bxem:mdXP0bY9vKG:owrFOt2gzSVh? M4W5dFI2ODh6MkCz
MCF7 EV MXrGeY5kfGmxbjDBd5NigQ>? NW\5bpZvOTBvMUCwJO69VQ>? NVz3Xml7OuLCiXi= NHjZfZBGXE:SIHnu[JVk\XNiQWTNJIFkfGm4YYTpc44> MnTCNlUxQDh{MEO=
MCF7 BMI1 M1;Me2Z2dmO2aX;uJGF{e2G7 MXmxNE0yODBizszN NH65VIoz6oDLaB?= NVy1T|J[TVSRUDDpcoR2[2W|IFHUUUBi[3SrdnH0bY9v M3rXR|I2ODh6MkCz
HepG2 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2rZeGROW00EoB?= Mlj5TWM2OD1|MD6xOuKhyrIEoECuOVDDqM7:TR?= MkfGNlUxPzh|MUG=
MOLT-3 M13iXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{LxfmROW00EoB?= NImw[5lKSzVyPUCuNFUyyqEEsdMgNE4xODMEoN88US=> NGLxelkzPTB5OEOxNS=>
HT1080 M1LF[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1rncVEuOTByIN88US=> M{H5fVQwOjRxNEigbC=> M2jyOWROW00EoB?= MXjpcoR2[2W|IHPlcIwh\GWjdHigd4lodmmoaXPhcpRtgSCrbjDhJJZmenlibH;3JINwdmOnboTyZZRqd25? MV:yOVA4QDB4NB?=
HT1080 NEW4T2hHfW6ldHnvckBCe3OjeR?= MonZNE4xODBzLUGwNEDPxE1? MmH4NU0zPCCq NXjPcoJ4TE2VT9Mg Ml3JbY5lfWOnczDwMZA2Oyi|ZYKxOUkhcW5iYn;0bEB1cW2nLTDhcoQh[2:wY3XueJJifGmxbj3k[ZBmdmSnboSgcYFvdmW{ MWqyOVA4QDB4NB?=
HT1080 Ml;KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWSwMlAxODFvMUCwJO69VQ>? MnP3NlQhcA>? M2DnVGROW00EoB?= NV7BTlRI[2G3c3XzJIFvKGmwY4LlZZNmKGmwIITo[UBvfW2kZYKgc4Yh[2WubIOgbY4hTzJxTTyge4hqdGViZHXjdoVie2mwZzDTJIFv\CCJMTDwbIF{\SClZXzsdy=> MXSyOVA4QDB4NB?=
HD-MY-Z MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUeyOE81QC95MjDo NF7ySYZKSzVy78{eNVAxKM7:TR?= MoPHNlUxPDh{M{[=
DOHH-2 MnnjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnzzNlQhcA>? MmfjTWM2OO,:nkGwNEDPxE1? NXfUNpZbOjVyNEiyN|Y>
DOHH-2 NXqwNXY1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2nVTlQ5KGh? M2\NVmlEPTB;MUmuPeKh|ryP M2\KPVI2ODR6MkO2
DOHH-2 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4Dz[lczKGh? MnfpTWM2OD13wrFOwG0> NEj1WJYzPTB2OEKzOi=>
REH NGXYd2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVSyOEBp MUnJR|UxRTBwMEK3xsDPxE1? MlHENlUxPDh{M{[=
REH NYfxRpJ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\nSIM1QCCq MVHJR|UxRTBwMEG0xsDPxE1? NH3TNWYzPTB2OEKzOi=>
REH NFrMTFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHPae444OiCq M2[2NmlEPTB;MD6wNVXDqM7:TR?= MoXHNlUxPDh{M{[=
HH MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NInOdoczPCCq MVXJR|UxRTFyND63xsDPxE1? MUWyOVA1QDJ|Nh?=
HH NXnpepdnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWm0PEBp MmjpTWM2OD12OD62xsDPxE1? NVKzSpBCOjVyNEiyN|Y>
HH MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXy4OIxGPzJiaB?= NYjXSZNDUUN3ME2xOE44yqEQvF2= MmC4NlUxPDh{M{[=
HuT-78 M2\odWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWGyOEBp NInKc3NKSzVyPUmuN:Kh|ryP MVuyOVA1QDJ|Nh?=
HuT-78 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1;XblQ5KGh? MY\JR|UxRTRwM9Mg{txO MnPoNlUxPDh{M{[=
HuT-78 M13ke2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGHMR5k4OiCq NV7Fdmt2UUN3ME20MlLDqM7:TR?= M3LBZlI2ODR6MkO2
OPM-2 M3LQOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;lNlQhcA>? M3PvNmlEPTB;MkSuNeKh|ryP NWK0Wm1wOjVyNEiyN|Y>
OPM-2 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYS0PEBp NFnUe21KSzVyPUVCpO69VQ>? NGLXSIgzPTB2OEKzOi=>
OPM-2 NXfXWHZKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm\2O|IhcA>? M13xTmlEPTB;MT6zxsDPxE1? MWiyOVA1QDJ|Nh?=
RPMI-8226 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;qfFI1KGh? NI\LcHlKSzVyPUGwOk43yqEQvF2= NYPPbHNrOjVyNEiyN|Y>
RPMI-8226 NVT4WZA5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYLsS|ZIPDhiaB?= MVnJR|UxRTlzLkJCpO69VQ>? MX:yOVA1QDJ|Nh?=
RPMI-8226 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkTmO|IhcA>? NXPIPItxUUN3ME2xOE46yqEQvF2= MVWyOVA1QDJ|Nh?=
U-266 M{\BZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1XU[VI1KGh? NEftU|lKSzVyPUi2MlLDqM7:TR?= NWXOW4l3OjVyNEiyN|Y>
U-266 NVLVbXA4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYW0PEBp NILoeXNKSzVyPU[4MlTDqM7:TR?= NF7j[XYzPTB2OEKzOi=>
U-266 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXP1RZR{PzJiaB?= NYHNb2dYUUN3ME2yO{41yqEQvF2= NXLKUWN7OjVyNEiyN|Y>
Kelly M{HCV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEX6cYUxNTFyIN88US=> M3zW[FczyqCq MWHJR|UxRTFwNUG4xsDPxE1? NV:xeZBbOjVyMEi5NFA>
SH-SY5Y  MkGzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3TKblAuOTBizszN MX23NuKhcA>? MnrTTWM2OD1yLke1OOKh|ryPwrC= MonXNlUxODh7MEC=
SK-N-AS NYG5NVBJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NILBV5IxNTFyIN88US=> NHPtdYM4OsLiaB?= M1HjUGlEPTB;MT63NVLDqM7:TdMg M3Szc|I2ODB6OUCw
SK-N-DZ MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYPp[5I4OC1zMDFOwG0> M{i5elczyqCq MWnJR|UxRTVwNEi1xsDPxE1? MV:yOVAxQDlyMB?=
HepG2 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGnD[pg1QMLiaB?= MWjEUXNQyqB? NWLuUWRGUUN3ME2xN{43PcLiwsJCpFAvQTMEoN88US=> NUTac5dIOjR7OU[xN|Y>
A549 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoS4OFjDqGh? M{Lie2ROW00EoB?= MX;JR|UxRTJ2MT65xsDDucLiM{GuNlPDqM7:TR?= NUm5e3RFOjR7OU[xN|Y>
MCF7 M2iwWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUO0V5pqPDkEoHi= MV\EUXNQyqB? NGTrRldKSzVyPUixMlA6yqEEsdMgNVQvOjIEoN88US=> NHTl[YMzPDl7NkGzOi=>
HL-60  MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGrP[VA4OsLiaB?= M4TQSWlEPTB;MD6xNwKBjc7:TR?= M3PEOFI1QTl|MEG0
HL-60[R] NGX4eW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWX4cYN4PzMEoHi= M{HRU2lEPTB;Mz6xNwKBjc7:TR?= Mom0NlQ6QTNyMUS=
MIAPACA MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3T6OWdKPTB;MT6zJOKyKDBwMEOg{txO MojjNlQ6PTN6MkG=
MCF-7 NFX2doxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7HTVUxRTBwMkWgxtEhOC5zIN88US=> M4HpbVI1QTV|OEKx
HeLa MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYjZb4U4T0l3ME2wMlY1KMLzIECuOEDPxE1? NHPmOlUzPDl3M{iyNS=>
MO59K  NUC1[GE{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkXvO{Bl NFOzU5dKSzVyPUCuNVfjiIYQvF2= NGKzT|IzPDl3M{W2NS=>
MO59J NHy1ZVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4PY[Fch\A>? MVLJR|UxRTBwMfMAie69VQ>? NInud2szPDl3M{W2NS=>
ME 180 MkfuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3:wV|Q5yqCqwrC= MXrJR|UxRThwOdMgxtHDqDBwM,MAie69VQ>? M{XDN|I1QTV|MEK3
MCF-7 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4HvSFQ5yqCqwrC= NVr5TI5[UUN3ME2yN{46KMLzIECuN-KBjc7:TR?= NGja[2szPDl3M{CyOy=>
HeLa NEDrT3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mkj5OFjDqGkEoB?= MoPMTWM2OD12LkexJOKyKDFwNPMAie69VQ>? NFjD[4gzPDl3M{CyOy=>
MDA-MB-453 Ml7zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX20POKhcMLi Ml\sTWM2OD1zMj61JOKyKDBwOEZihKXPxE1? MYiyOFk2OzB{Nx?=
MDA-MB-231 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVTjeGVrPDkEoHlCpC=> MXXJR|UxRTJ2LkKyJOKyKDJwOUVihKXPxE1? MkPJNlQ6PTNyMke=
PC-3 NI\2[VFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX60POKhcMLi M4S2emlEPTB;MUSuOEDDuSB|LkKz5qCG|ryP NG\KZWQzPDl3M{CyOy=>
HT-29 NFnS[|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{jiS|Q5yqCqwrC= NHvSR45KSzVyPUKxMlQ2KMLzIEOuPFfjiIYQvF2= NEDoNlYzPDl3M{CyOy=>
BGC-823 NVzGOI9kT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVrxfmVxPDkEoHlCpC=> NV\QcYN[UUN3ME20N{44PCEEsTC1MlE{6oDHzszN NHPMb2czPDd7M{i3Oy=>
HeLa M{jrTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXXBbI5{PDkEoHlCpC=> NFW2bnFKSzVyPUKwPU46OCEEsTCxN{41OiEkgJZOwG0> NUnBb2NZOjR5OUO4O|c>
A549 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUS0POKhcMLi MoL0TWM2OD1zM{muOVQhyrFiNz6wOgKBjc7:TR?= NXXreYtKOjR5OUO4O|c>
HK-2 NYnaT2lOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXm0POKhcMLi MYTJR|UxRTlwMUegxtEhOS53OPMAie69VQ>? M{PNdVI1Pzl|OEe3

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p53 / p-p53 / Acetyl-p53 / TF-IIB; 

PubMed: 23800173     


Western blotting analysis of p53 levels and the indicated p53 post-translational modifications in the nucleus and cytoplasm of U-2 OS cells treated with no drug, 1 μmol/l etoposide (treated for 24 hours) and 100 μmol/l etoposide (treated for 12 hours), re䲧疝Ỵ疞㧀疜膉痘 瘿삨ՂᾰƌՂĀ 㺣痖帉痖Ѐ瑖堘𢡄빢᎒ՂĀ鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙圭堙𢡄玚Wᾰƌ ᾰƌ戤瘯Ɖ뙠ෆ䐺痖暼瘿뙠ෆᾰƌ 뙠ෆÐ㺣

p53 / p21 / c-Myc / PARP ; 

PubMed: 20212154     


Myc is repressed at the posttranscriptional level following etoposide treatment. HEK293 cells were treated with etoposide at the indicated concentrations for 24 h. Parallel samples were taken for western and northern analysis as indicated. 

23800173 20212154
Immunofluorescence
COX IV; 

PubMed: 29221178     


Panel 1 (untreated) depicts the mitochondrial distribution by visualizing the expression of Cox IV in U87(WT) cells. Panel 2 (etoposide treated) represents the distribution of mitochondria in U87(RETO) cells after 10 days of drug exposure as visualized by䲧疝Ỵ疞㧀疜膉痘 瘿삨ՂᾰƌՂĀ 㺣痖帉痖Ѐ瑖堘𢡄빢᎒ՂĀ鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙圭堙𢡄玚Wᾰƌ ᾰƌ戤瘯Ɖ

γH2AX / pATM ; 

PubMed: 19858003     


HeLa cells were treated with vehicle (Ctl), 6 Gy IR (IR) or 25 μM etoposide (ETO). Co-localization (yellow signal in the overlay (OL)) of gH2AX (red) and pATM (green). Scale bar = 20 μm.

MDC1; 

PubMed: 19858003     


HeLa cells were treated with vehicle (Ctl), 6 Gy IR (IR) or 25 μM etoposide (ETO). Co-localization of gH2AX with MDC1.

pDNA-PKcs; 

PubMed: 19858003     


HeLa cells were treated with vehicle (Ctl), 6 Gy IR (IR) or 25 μM etoposide (ETO). Co-localization of gH2AX with pDNA-PK.

p53; 

PubMed: 27515249     


p53 localization in untreated and 12-h etoposide treated CD41+ MK cells. Cells were stained with anti-p53 antibody. TOTO-3 was used to stain the nucleus. Scale bar=20 μm.

YAP; 

PubMed: 27515249     


(D) YAP localization in untreated CD41+MK cells and CD41+ MK cells treated by 10 μM etoposide for five hours on day 10 of culture. Cells were stained with anti-YAP antibody. DAPI was used to stain the nucleus. Cells (150) were counted and categorized acco䲧疝Ỵ疞㧀疜膉痘 瘿�෋ᾰƌ෋à 㺣痖帉痖Ѐ瑖堘𢡄빢᎒෋à鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙圭堙𢡄玚Wᾰƌ ᾰƌ戤瘯Ɖ삨Ղ䐺痖暼瘿삨Ղᾰƌ 삨ՂÐ㺣痖삨Ղ€𢡄사Ղ€䀷痗사Ղ౴사Ղ㵶痗사Ղ뺖᎒泌Itemセ᎒Count﫨呂샜Ղ

29221178 19858003 27515249
Growth inhibition assay
Cell viability ; 

PubMed: 22615609     


Effect of etoposide on HEK293 cell viability. Cells were seeded at 104 in 96-well plates and treated with etoposide (50,100,150 and 200µM) for 24 hrs and compared to nontreated cells (control). At the end of treatment period, cell viability was measured u䲧疝Ỵ疞㧀疜膉痘 瘿삨ՂᾰƌՂĀ 㺣痖帉痖Ѐ瑖堘𢡄빢᎒

22615609
体内研究 Etoposide 作用于Lewis 肺癌,诱导肿瘤免疫。Etoposide按50 mg/kg剂量单独腹腔注射给药注射了Lewis肺癌细胞 (3LL)的C57B1/6小鼠,诱导60%存活。[4]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:[5]
+ 展开

Topoisomerase II 活性测定:

制备核提取物,进行核分离。在Topoisomerase II去连环过程中获得去连环百分数而计算Topoisomerase II的活性。氚标记的kinoplast DNA (KDNA 0.22 μg)作为底物。Etoposide 与 Topoisomerase II在37°C 下温育30分钟,然后加入1%十二烷基硫酸钠(SDS)和蛋白酶K(100 μg/mL)终止。通过Etoposide获得去连环百分数和 Topoisomerase II 抑制情况。
细胞实验:[5]
+ 展开
  • Cell lines: 人类胶质瘤细胞系CL5
  • Concentrations: 80 μg/mL
  • Incubation Time: 1 小时
  • Method: Etoposide处理后,使用含有0.03%胰蛋白酶和0.27 mM乙二胺四乙酸(EDTA)的磷酸盐缓冲液(PBS)将细胞从培养皿中移去,然后在培养皿中稀释到适当数目,获得20到200个菌落。12天后,使用甲醇-乙酸固定培养基,使用结晶紫进行染色,并计数超过50个细胞的菌落。
    (Only for Reference)
动物实验:[2]
+ 展开
  • Animal Models: 携带血管肉瘤移植瘤ISOS-1 的小鼠
  • Formulation: 生理盐水
  • Dosages: 10 mg/kg
  • Administration: 从实验第7天开始,每天腹腔注射,持续5天
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 100 mg/mL (169.9 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
5% DMSO+30% PEG 300+H2O
15mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 588.56
化学式

C29H32O13

CAS号 33419-42-0
稳定性 powder
in solvent
别名 VP-16, VP-16213

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03811002 Not yet recruiting Limited Stage Lung Small Cell Carcinoma|Stage IIB Lung Cancer AJCC v8|Stage III Lung Cancer AJCC v8|Stage IIIA Lung Cancer AJCC v8|Stage IIIB Lung Cancer AJCC v8|Stage IIIC Lung Cancer AJCC v8 National Cancer Institute (NCI) September 6 2019 Phase 2|Phase 3
NCT03811002 Not yet recruiting Limited Stage Lung Small Cell Carcinoma|Stage IIB Lung Cancer AJCC v8|Stage III Lung Cancer AJCC v8|Stage IIIA Lung Cancer AJCC v8|Stage IIIB Lung Cancer AJCC v8|Stage IIIC Lung Cancer AJCC v8 National Cancer Institute (NCI) September 6 2019 Phase 2|Phase 3
NCT03349346 Withdrawn Diffuse Large B-Cell Lymphoma|Mediastinal B-cell Lymphoma Gilead Sciences June 2019 Phase 1
NCT03349346 Withdrawn Diffuse Large B-Cell Lymphoma|Mediastinal B-cell Lymphoma Gilead Sciences June 2019 Phase 1
NCT03864419 Not yet recruiting Burkitt Lymphoma|KSHV-associated Multicentric Castleman Disease|Diffuse Large B-Cell Lymphoma Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI) May 4 2019 Phase 1
NCT03864419 Not yet recruiting Burkitt Lymphoma|KSHV-associated Multicentric Castleman Disease|Diffuse Large B-Cell Lymphoma Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI) May 4 2019 Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    Regarding the Etoposide S1225, do you have any data of the inhibition sepcificity of this product? It will inhibit other enzymes other than TOP2A?

  • 回答:

    According to the available published data, the inhibition of Etoposide is specific to TOP2A. But there're also two papers showing that Etoposide could inhibit the p34cdc2 Kinase Activity: 1. http://cancerres.aacrjournals.org/content/52/7/1817.short ; 2. http://cancerres.aacrjournals.org/content/50/12/3761.short.

Topoisomerase Signaling Pathway Map

相关Topoisomerase产品

Tags: 购买Etoposide | Etoposide供应商 | 采购Etoposide | Etoposide价格 | Etoposide生产 | 订购Etoposide | Etoposide代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID